The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is set to host a webinar aimed at helping members bolster their leadership skills. The webinar, "Pathways to ISPOR Leadership," is set for 10 a.m. EST July 14. To learn more, click here. […]
ICER to Assess Roxadustat for Treatment Anemia in Chronic Kidney Disease
The Institute for Clinical and Economic Review (ICER) announced plans to assess FibroGen's roxadustat for the treatment of anemia in chronic kidney disease. An open input period will remain open until 5 p.m. EST July 15. According to a press release, a document outlining the planned review […]
ISPOR Offers Short Courses on Medical Devices, Payment Models
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is offering short courses on medical devices and different payment models for drugs and other products. Below are the two intermediate courses: Market Access & Value Assessment of Medical Devices, 10 a.m. EST […]
PBMs Report Ease in Demand for Hydroxychloroquine
Pharmacy benefit managers last month reported an easing of demand for the antimalarial drug hydroxychloroquine following a rapid surge spurred by comments by the White House, Specialty Pharmacy Continuum reports. The Trump administration had in the past suggested the drug was an effective […]
Valid Insight Report Explores Insights from Roundtable on Payer Engagement
A new report from Valid Insight explores key insights generated from a roundtable discussion on payer engagement. The white paper, "Excellence in Payer Engagement: Strategic Outputs From A Roundtable Discussion," includes input from a number of stakeholders in the pharmaceutical […]
Podcast Highlights ‘Buy and Bill’ Model in Oncology
Memorial Sloan Kettering Cancer Center's Dr. Aaron Mitchell in the latest Relentless Health Value podcast discusses the "buy and bill" payment model in oncology. Mitchell is an oncologist and health services researcher. The podcast explores how hospitals are reimbursed for infusing high-cost […]
OptumRx: Rising Orphan Drug Competition Could Lead to Lower Prices
Increased competition in the orphan drug market could ultimately help pull down prices, OptumRx suggests in a new report. According to the report, roughly 40 percent of drugs approved this year will be orphan drugs. "What is new is that we now are starting to see the development of orphan […]
ACR Tapped as Imaging Partner for COVID-19 Registry
The Society of Clinical Care Medicine (SCCM) has chosen the American College of Radiology (ACR) to be the main imaging repository for a COVID-19 registry. The Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS) registry is part of an initiative aimed at developing a […]
Report: HEOR Services Market Poised for Rapid Growth
The health economics and outcomes research (HEOR) services market is set to see "rapid growth" between 2020-2025, according to a new report by Reports Intellect. The report profiles a number of companies, including Axtria, Avalon Health Economics, ICON, McKesson, PAREXEL and Syneos Health. To […]
NPC: ‘Ready, aim, fire’ Mentality Detrimental in Health Care
Having a "ready, aim, fire" mentality can prove harmful when sharing health care information, the National Pharmaceutical Council (NPC) writes in a recent blog post. NPC points to the Institute for Clinical and Economic Review's (ICER) report on COVID-19 treatments, calling it "a prime example of […]
Legislation Aims to Prevent Pharma From Price-gouging During Pandemic
Two new bipartisan bills introduced by House Democrats aim to prevent the pharmaceutical industry from engaging in price-gouging on COVID-19 treatments, according to a Common Dreams report. The legislation was introduced following a recent poll that found a whopping 88 percent of Americans fear […]
Report Reveals Racial Disparities in COVID-19 Outcomes
New data released by the government on Monday suggests black Americans under Medicare were roughly four times more likely as white Americans to be hospitalized for COVID-19, Reuters reports. The data was released by the Centers for Medicare and Medicaid Services. "The disparities in the data […]
‘Domestic Reference Pricing’ for COVID-19 Drugs?
While the Trump administration has in the past proposed international reference pricing for drug pricing in the U.S., a Health Affairs blog post suggests domestic reference pricing for COVID-19 therapies. Domestic reference pricing, Sean Dickson and Timothy Lash write, could help drive pricing […]
NPC Plans Webinar in Prices for COVID-19 Drugs
An upcoming webinar hosted by the National Pharmaceutical Council (NPC) will discuss a range of pricing-related issues for COVID-19 drugs. The online event, set to begin 3:30 p.m. EST July 14, will offer key insights from a panel of industry experts. Panelists include: Peter Bach, MD, […]
Hahn: Some COVID-19 Changes to Remain
Food and Drug Administration (FDA) Chief Stephen Hahn recently said some changes made to address COVID-19 will remain in place, Medical Design & Outsourcing reports. Hahn made the comments June 19 during a meeting with members of the Medical Device Innovation Consortium, according to the […]
Informa Pharma Intelligence Plans 24-Hour Webinar Series
Informa Pharma Intelligence is set to host a free, 24-hour interactive webinar series on the latest insights into COVID-19. The event is set to begin 4 a.m. EST. "This webinar event is meant to act as a true resource in compiling top industry insights on not only what's happening today, but […]
Blog Post Explores Novel Value Elements for Assessment of COVID-19 Drugs
A recent Health Affairs blog post suggests the inclusion of more novel value elements in the assessment of COVID-19 drugs is necessary. The blog post by Sachin Kamal-Bahl et al. offers a look at a number of non-traditional value elements, including fear of contagion, insurance and uncertainty, as […]
ISPOR-FDA Summit Transitions to Virtual Event
The International Society for Pharmacoeconomics and Outcomes Research's (ISPOR) announced that the joint ISPOR-FDA Summit 2020, set for Sept. 29, will be a virtual event this year. ISPOR and the FDA Center for Devices and Radiological Health are hosting the one-day event. "Virtual ISPOR-FDA […]
Cytel Offers On-Demand Access to Webinar on Synethic, External Control Arms
A new on-demand webinar from Cytel offers insights into synthetic and external control arms in clinical trials. The webinar features Cytel Real-World Evidence Senior Vice President Kristian Thorlund. Cytel also recently published a new scientific primer on using synthetic control arms in place […]
Opinion: Move Forward with Evidence-based Care as Foundation
Evidence-based care should be the bedrock of health care moving forward, the authors of a recent opinion piece published on The Hill suggest. The authors, John Rother, president of the National Coalition on Health Care, Katy Spangler, Smarter Health Care Coalition co-director, and Mark Fendrick, […]
Cytel Paper Offers Insight into Trial Recruitment Targets
A new white paper from Cytel offers insight into how recruitment targets are "met with sound starting assumptions and key modeling techniques." "In order to maximize the potential to achieve recruitment milestones and to avoid misleading trial projections, planning must take careful precautions […]
How Can HEOR Boost Outcomes?
The health economics and outcomes research (HEOR) framework can help facilitate more robust decision-making using "powerful data and insights," ISPOR Associate CSO Lucinda Orsini writes in an article published on HIMSS. "While both health economics and outcomes research can be performed in […]
Blog Post Touts VA, ICER Partnership as ‘Highly Beneficial’
The partnership between the Department of Veterans Affairs (VA) and the Institute for Clinical and Economic Review (ICER) has provided benefits across a number of fronts, according to a Health Affairs blog post by representatives of the agency and drug pricing watchdog. Despite concerns that the […]
Kreis: Challenging Price of Costly CF Drug Not ‘Discrimination’
Maurice Kreis, head of the New Hampshire Office of the Consumer Advocate, says challenging the price of Vertex Pharmaceuticals' cystic fibrosis drug is not "discrimination." Kreis, whose 18-year-old daughter has cystic fibrosis, was referring to how some critics responded to ICER's suggestion […]
Study Suggests Pfizer’s Vyndaqel is Too Expensive
A recent study published in JAMA Cardiology suggests the price tag on Pfizer's Vyndaqel is too high. According to a FiercePharma article, the heart medication received FDA approval in 2019, and hit the market with a $225,000 per year price tag. "Unfortunately, the high copays required by the […]
Sarepta Therapeutics’ Berry Talks Access to Rare Disease Treatments
Sarepta Therapeutics' Diane Berry in a recent Patients Rising Podcast discussed access to treatments for rare diseases. Berry is Sarepta Therapeutics' senior vice president of global health policy. "Patients with rare diseases may soon have better access to treatments," a description of the […]
ICER to Review Most Significant Drug Price Hikes
The Institute for Clinical and Economic Review (ICER) is set to review whether the most significant drug price increases are evidence-based. ICER on Friday released an updated protocol for the annual assessment. An open input period on the drugs tapped for review began Friday, June 19, and […]
Study: Almost 9 in 10 Concerned about High Drug Prices Due to COVID-19
Almost nine in 10 adults in the U.S. are either "very" (55 percent) or "somewhat" (33 percent) concerned pharma will use the COVID-19 pandemic to hike drug prices, according to a new study by West Health and Gallup. "As Americans brace for a potential second wave of coronavirus infections later […]
Updated Guide to HEOR/Market Access Writing Release
The 2020 update to "Evidence generation and communication: a guide to getting started in HEOR/market access medical writing" has been released. The guide is free to read, and is available online in PDF format. "This guide focuses on medical writing roles in the HEOR/market access arenas, but […]
ISPOR Offering Short Courses on Value Assessment Frameworks, HTA
The International Society of Pharmacoeconomics and Outcomes Research (ISPOR) is offering two short, online courses. Below are the two courses: A Health Economics Approach to US Value Assessment Frameworks, 10 a.m. EST June 23 Introduction to Health Technology Assessment, 10 a.m. EST June […]
